ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

ClinicalTrials.gov ID: NCT05536973

Public ClinicalTrials.gov record NCT05536973. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]

Study identification

NCT ID
NCT05536973
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Enrollment
69 participants

Conditions and interventions

Interventions

  • ADVM-022 Genetic

Genetic

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 22, 2022
Primary completion
Aug 25, 2024
Completion
Jul 31, 2028
Last update posted
Aug 21, 2025

2022 – 2028

United States locations

U.S. sites
34
U.S. states
16
U.S. cities
33
Facility City State ZIP Site status
Adverum Clinical Site 178 Phoenix Arizona 85020
Adverum Clinical Site 126 Phoenix Arizona 85053
Adverum Clinical Site 159 Tucson Arizona 85704
Adverum Clinical Site 100 Beverly Hills California 90211
Adverum Clinical Site 172 Encino California 91436
Adverum Clinical Site 169 Fullerton California 92835
Adverum Clinical Site 170 Pasadena California 91105
Adverum Clinical Site 174 Poway California 92064
Adverum Clinical Site 164 Riverside California 92505
Adverum Clinical Site 166 Sacramento California 95817
Adverum Clinical Site 175 Santa Barbara California 93103
Adverum Clinical Site 116 Lakewood Colorado 80228
Adverum Clinical Site 165 Waterford Connecticut 06385
Adverum Clinical Site 124 Deerfield Beach Florida 33064
Adverum Clinical Site 176 Fort Lauderdale Florida 33308
Adverum Clinical Site 168 Jacksonville Florida 32216
Adverum Clinical Site 149 ‘Aiea Hawaii 96701
Adverum Clinical Site 167 Detroit Michigan 48201
Adverum Clinical Site 161 Royal Oak Michigan 48073
Adverum Clinical Site 163 Southaven Mississippi 38671
Adverum Clinical Site 177 Omaha Nebraska 68105
Adverum Clinical Site 119 Reno Nevada 89502
Adverum Clinical Site 146 Cherry Hill New Jersey 08034
Adverum Clinical Site 171 Teaneck New Jersey 07666
Adverum Clinical Site 122 West Columbia South Carolina 29169
Adverum Clinical Site 144 Rapid City South Dakota 57701
Adverum Clinical Site 101 Nashville Tennessee 37203
Adverum Clinical Site 123 Abilene Texas 79606
Adverum Clinical Site 154 Austin Texas 78705
Adverum Clinical Site 108 Bellaire Texas 77401
Adverum Clinical Site 162 McAllen Texas 78503
Adverum Clinical Site 151 San Antonio Texas 78240
Adverum Clinical Site 107 The Woodlands Texas 77384
Adverum Clinical Site 152 Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05536973, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 21, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05536973 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →